Evofem Biosciences, Inc. (EVFM) › Cash & EquivalentsEvofem Biosciences, Inc. (EVFM) — Cash & EquivalentsAnnual figures by fiscal year, from SEC filings.2012: $11.10M2013: $4.36M2014: $75.95M2015: $37.75M2016: $11.48M2017: $1.21M2018: $1.33M2019: $15.57M2020: $48.89M2021: $7.73M2022: $2.77M2024: $741.0K2025: $578.0K$578.0K2012Cash & Equivalents (USD)2025Fiscal YearCash & EquivalentsChange YoY2025$578.0K-22.0%2024$741.0K—2022$2.77M-64.2%2021$7.73M-84.2%2020$48.89M+214.0%2019$15.57M+1070.8%2018$1.33M+9.8%2017$1.21M-89.4%2016$11.48M-69.6%2015$37.75M-50.3%2014$75.95M+1640.3%2013$4.36M-60.7%2012$11.10M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share